Real-time insights. Smarter decisions. Better trades.
🔍 Search Stocks 14 day Free Trial
LUMOS DIAGNOSTICS HOLDINGS LIMITED (LDX)ASX AI Signals has generated 4 signal for LDX during the last 90 days, indicating active trading activity and ongoing AI monitoring
Latest LDX Signals | |
| 22/05/2026 | SELL |
| 18/05/2026 | SELL |
| 17/05/2026 | SELL |
LDX Share Price | |
| Current Price | $0.105 |
| 52 Week High | $0.320 |
| 52 Week Low: | $0.027 |
| Trading at (% of 52 Week High) | 32.81% |
Lumos Diagnostics Holdings Limited (ASX: LDX) develops and markets rapid urine drug testing devices and related diagnostic products. The company provides technology solutions that enable quick and accurate drug screening results for medical, workplace, and forensic use. Lumos serves healthcare professionals and organizations globally with its easy-to-use diagnostic tools.
The Health Care Equipment & Services sector on the ASX includes companies that produce medical devices, equipment, and supplies, as well as those providing healthcare-related services. This sector covers a wide range of products such as surgical instruments, diagnostic machines, and health monitoring devices. It also includes businesses involved in healthcare management, medical laboratories, and support services. These companies play a key role in supporting hospitals, clinics, and other healthcare providers to improve patient care. The sector is influenced by factors like technological advances, regulatory changes, and demand for healthcare services.
The SELL recommendation for LDX is supported by weak price performance and potential liquidity concerns at the current low price level. However, limited publicly available financial data and market volatility introduce some uncertainty.
Lumos sets Q3 reporting date, investor webinar as SPP enters final stretch Proactive uses images sourced from Shutterstock
Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) has locked in the timing for its March quarter update and investor briefing, while reminding shareholders that its current c Lumos secures US$5m FebriDx milestone payment as US rollout gains traction Proactive uses images sourced from Shutterstock
Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) has received a US$5 million milestone pre-payment from its US distribution partner Phase Scientific, with its FebriDx® point Lumos lifts operating cash flow on FebriDx momentum as 1H FY26 loss widens Proactive uses images sourced from Shutterstock
Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) has reported revenue of US$6.12 million for the six months to December 31, 2025 (1H FY26), down slightly from US$6.31 millio SARASOTA, Fla., June 21, 2022 (GLOBE NEWSWIRE) -- Lumos Diagnostics (ASX:LDX), a leader in rapid point-of-care (POC) diagnostic technologies, announced today that its Board of Directors has appointed Doug Ward, a highly experienced diagnostics executive, to serve as CEO.
“We are delighted to welcLatest LUMOS DIAGNOSTICS HOLDINGS LIMITED(LDX) News
Lumos sets Q3 reporting date, investor webinar as SPP enters final stretch
Lumos secures US$5m FebriDx milestone payment as US rollout gains traction
Lumos lifts operating cash flow on FebriDx momentum as 1H FY26 loss widens
Lumos Diagnostics Appoints Doug Ward as CEO
Get access to daily BUY & SELL signals, advanced AI analysis, watchlists and email alerts.
14 Day Free Trial • Cancel Anytime • Founders Price $15/month
Start My Free Trial